Participants:18–64 years · 65+ years
Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide

Contact Research Centre

Acute kidney injury

Not recruiting

Registered drug

Study on Ravulizumab for Protecting Chronic Kidney Disease Patients from Acute Kidney Injury After Heart Surgery

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Ravulizumab

Contact Research Centre

Neoplasm

Not recruiting

Registered drugNo placebo

Study of CFT1946 alone and with trametinib or cetuximab in patients with BRAF-V600 mutant solid tumors who have received standard treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cetuximab

Contact Research Centre

Neoplasm malignant

Not recruiting

InvestigationalNo placebo

Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Darolutamide

Contact Research Centre

Neoplasm

Not recruiting

Registered drugNo placebo

Study of BMS-986408 Alone or with Nivolumab and Ipilimumab for Patients with Advanced Solid Tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bms-986408

Contact Research Centre

Study on the Safety and Effectiveness of THE-630 for Patients with Advanced Gastrointestinal Stromal Tumors (GIST)

Not recruiting

InvestigationalNo placebo

Study on the Safety and Effectiveness of THE-630 for Patients with Advanced Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:The-630

Contact Research Centre

Endometrial cancer+4

Not recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of SKB264 and Pembrolizumab for Patients with Cervical, Urothelial, Ovarian, or Prostate Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anhydrous Caffeine

Contact Research Centre

Breast cancer+2

Not recruiting

Registered drugNo placebo

Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Alpelisib

Contact Research Centre

Focal segmental glomerulosclerosis

Not recruiting

Registered drug

Study on the Effectiveness and Safety of DMX-200 with Losartan in Adults with Focal Segmental Glomerulosclerosis

Registered drug

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Azilsartan Medoxomil

Contact Research Centre

Cardiovascular disorder

Not recruiting

Registered drug

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid

Contact Research Centre

Neoplasm

Not recruiting

InvestigationalNo placebo

Study of NGM707 and Pembrolizumab for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ngm707

Contact Research Centre

Find therapies in clinical trials near you – page 92

1 156 trials match your criteria

Malignant melanoma

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Hidradenitis

Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

Acute kidney injury

Study on Ravulizumab for Protecting Chronic Kidney Disease Patients from Acute Kidney Injury After Heart Surgery

Neoplasm

Study of CFT1946 alone and with trametinib or cetuximab in patients with BRAF-V600 mutant solid tumors who have received standard treatment

Neoplasm malignant

Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

Neoplasm

Study of BMS-986408 Alone or with Nivolumab and Ipilimumab for Patients with Advanced Solid Tumors

Study on the Safety and Effectiveness of THE-630 for Patients with Advanced Gastrointestinal Stromal Tumors (GIST)

Study on the Safety and Effectiveness of THE-630 for Patients with Advanced Gastrointestinal Stromal Tumors (GIST)

Endometrial cancer+4

Study on the Safety and Effectiveness of SKB264 and Pembrolizumab for Patients with Cervical, Urothelial, Ovarian, or Prostate Cancer

Breast cancer+2

Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Focal segmental glomerulosclerosis

Study on the Effectiveness and Safety of DMX-200 with Losartan in Adults with Focal Segmental Glomerulosclerosis

Cardiovascular disorder

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Neoplasm

Study of NGM707 and Pembrolizumab for Patients with Advanced or Metastatic Solid Tumors

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.